Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.47 |
| ▸ | FLT3 | P36888 | 10/20 | 0.47 |
| ▸ | KIT | P10721 | 10/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.47 |
| ▸ | MET | P08581 | 3/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.47 |
| ▸ | PRKACA | P17612 | 2/20 | 0.47 |
| ▸ | LTK | P29376 | 2/20 | 0.47 |
| ▸ | GRK5 | P34947 | 2/20 | 0.47 |
| ▸ | CDK8 | P49336 | 2/20 | 0.47 |
| ▸ | CDK7 | P50613 | 2/20 | 0.47 |
| ▸ | CDK9 | P50750 | 2/20 | 0.47 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.47 |
| ▸ | MST1R | Q04912 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17030757 | 0.86 | KDR (0.50) | KDRFLT3KITAURKBMET | |
| SCHEMBL20963390 | 0.83 | KDR (0.47) | KDRFLT3KITAURKBMET | |
| SCHEMBL17278412 | 0.81 | KCNA5 (0.39) | KDRFLT3KITAURKBMET | |
| SCHEMBL24402745 | 0.81 | KCNA5 (0.42) | KDRFLT3KITAURKBMET | |
| SCHEMBL21609072 | 0.79 | KDR (0.50) | KDRFLT3KITAURKBMET | |
| SCHEMBL15907821 | 0.73 | KDR (0.37) | KDRFLT3KITAURKBMET | |
| SCHEMBL16646799 | 0.73 | KDR (0.57) | KDRFLT3KITAURKBMET | |
| SCHEMBL2882058 | 0.73 | KDR (0.57) | KDRFLT3KITAURKBMET | |
| SCHEMBL2445430 | 0.72 | KDR (0.58) | KDRFLT3KITAURKBMET | |
| Hydrochloric Acid SCHEMBL5103456 | 0.71 | KDR (0.56) | KDRFLT3KITAURKBMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771664-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771664-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11583529-B2 | Treatment of inflammatory disorders | ALDEYRA THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220202745-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
| US-20170239196-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2017-08-24 | — | — | US | disclosed |
| US-9687481-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9687481-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| WO-2017035082-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-20150344447-A1 | NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION | ALDEXA THERAPEUTICS, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150344447-A1 | NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION | ALDEXA THERAPEUTICS, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150335632-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2015-11-26 | — | — | US | disclosed |
| US-20150335632-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2015-11-26 | — | — | US | disclosed |
| WO-2014116836-A2 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEXA THERAPEUTICS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014116593-A1 | NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION | ALDEXA THERAPEUTICS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | KDR 4522/4885FLT3 3169/4885KIT 3044/4885 |
| US-11583529-B2 | Treatment of inflammatory disorders | TNF, NFKBIA, LTB4R2 | KDR 4522/4885FLT3 3169/4885KIT 3044/4885 |
| US-20170239196-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | KDR 1942/4885FLT3 4802/4885KIT 2641/4885 |
| US-20150344447-A1 | NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION | PDE6C, PDE6D, PDE6A | KDR 336/4885FLT3 3462/4885KIT 2551/4885 |
| US-11771664-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | KDR 1942/4885FLT3 4802/4885KIT 2641/4885 |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | KDR 1942/4885FLT3 4802/4885KIT 2641/4885 |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | KDR 4522/4885FLT3 3169/4885KIT 3044/4885 |
| US-20220202745-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | KDR 1942/4885FLT3 4802/4885KIT 2641/4885 |
| US-20150335632-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | KDR 1942/4885FLT3 4802/4885KIT 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.